vimarsana.com

Latest Breaking News On - Late stage emerging therapies - Page 16 : vimarsana.com

LYBALVI: An Oral Atypical Antipsychotic Drug for the Treatment of Adults with Schizophrenia and Bipolar I Disorder - Drug Insight Analysis and Market Forecasts to 2032

/PRNewswire/ The "LYBALVI Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com s offering. "This "LYBALVI Drug.

United statesUnited kingdomLaura woodOffice hours callClinical developmentE st office hours callMarket forecastTopics coveredMarketed therapiesLate stage emerging therapiesFree callHours callResearch and markets

ABILIFY MYCITE: A Drug-device Combination Comprised of Aripiprazole Tablets Embedded with an IEM - Drug Insights and Market Forecasts 2019-2022 & 2023-2032

/PRNewswire/ The "ABILIFY MYCITE Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com s offering. "This "ABILIFY.

United statesUnited kingdomLaura woodOffice hours callClinical developmentE st office hours callMarket forecastIngestible event markerTopics coveredMarketed therapiesLate stage emerging therapiesFree callHours call

Europe Waylivra (volanesorsen) Market Drug Insights and

Dublin, March 03, 2023 (GLOBE NEWSWIRE) The "Europe WAYLIVRA Market Drug Insight and Market Forecast - 2032" drug pipelines has been added to .

United kingdomClinical developmentDrug insightMarket forecastTopics coveredMarketed therapiesLate stage emerging therapiesResearch and marketsCardiovascular drugs

United States DEXTENZA Drug Insight and Market Forecast Report 2022-2032: MoA, Dosage and Administration, R&D Activities, Regulatory Milestones

DUBLIN, Feb. 16, 2023 The "United States DEXTENZA Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com s offering..

United statesLaura woodE st office hours callOffice hours callClinical developmentMarket forecastPostoperative painTopics coveredMarketed therapiesLate stage emerging therapiesStates marketFree callHours callResearch and marketsHealth care amp hospitalsMedical pharmaceuticals

KUVAN (Sapropterin Hydrochloride): Indicated to Reduce Blood Phe Levels in Patients with HPA Due to Tetrahydrobiopterin (BH4) Responsive PKU

/PRNewswire/ The "KUVAN (Sapropterin Hydrochloride), Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com s offering..

United statesUnited kingdomMerck seronoLaura woodE st office hours callOffice hours callClinical developmentSapropterin hydrochlorideDrug insightMarket forecastPhenylalanine hydroxylaseTopics coveredMarketed therapiesLate stage emerging therapiesFree callHours call

vimarsana © 2020. All Rights Reserved.